Drug intelligence / Profile preview

RK017

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK017 is a protein-based therapeutic candidate currently in the research and development phase at RevolKa. The drug is being developed using RevolKa's proprietary "evolvability" platform, which utilizes a directed evolution approach to optimize protein functions for therapeutic use. As of the current pipeline disclosure, the specific molecular target and therapeutic indication for RK017 have not been revealed, and the project is categorized as "Working" in the company's development sequence.

Other names: RK017-RevolKa-proteinRK-017-RevolKa-proteinRK 017-RevolKa-protein

Beyond the preview

Go deeper on RK017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK017.

Explore the full profile